aevi-007
mAbexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 31, 2020 (NCT04671251)
Timeline
Indications
Mechanism of action
- Interleukin-18INHIBITOR
IL18 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06436183 | Phase 2 | May 1, 2024 | Apollo Therapeutics Ltd |
| NCT04752371 | Phase 1 | Mar 25, 2021 | Cerecor Inc, Ghent University |
| NCT04671251 | Phase 1 | Dec 31, 2020 | Aevi Genomic Medicine |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Aevi Genomic Medicine | For profit | 1 | 1 | 1 | 2020 |
| Apollo Therapeutics Ltd | For profit | 1 | 1 | 1 | 2024 |
| Cerecor Inc | For profit | 1 | 1 | 1 | 2021 |
| Ghent University | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1